i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC). 

In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity!

Click below to complete the claim your CE credit:
Module 1: https://bit.ly/49NCaQu

Click below to complete the next Module in this series, Current and Emerging Treatments for HER2-Mutated NSCLC
Module 2: https://bit.ly/405xEJO

Additional Advances in HER2-Mutated NSCLC With Julia Kathleen Rotow, MD + Activity Module 1

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Additional Advances in HER2-Mutated NSCLC With Julia Kathleen Rotow, MD + Activity Module 1

Oncology Data Advisor®